儿童耐药肺炎支原体DNA载量与23sRNA基因2063位点突变的相关性分析

朱美君; 季菊花; 朱洁; 宋磊; 周峰; 赵金华

doi:10.11852/zgetbjzz2020-1544

PDF(565 KB)

中国儿童保健杂志 ›› 2021, Vol. 29 ›› Issue (9) : 1017-1020. DOI: 10.11852/zgetbjzz2020-1544

临床研究与分析

儿童耐药肺炎支原体DNA载量与23sRNA基因2063位点突变的相关性分析

朱美君¹, 季菊花¹, 朱洁¹, 宋磊¹, 周峰², 赵金华¹

作者信息 +

Study on the correlation between DNA load of drug-resistance mycoplasma pneumoniae and 23sRNA mutation at 2063 locus in children

ZHU Mei-jun^*, JI Ju-hua, ZHU Jie, SONG Lei, ZHOU Feng, ZHAO Jin-hua

Author information +

文章历史 +

摘要

目的分析儿童耐药支原体肺炎的肺炎支原体(MP)DNA载量与23sRNA2063位点突变的相关性,以期为MP肺炎的治疗提供参考。方法选取2017年12月-2019年12月在南通市第一人民医院治疗的MP肺炎患儿158例,对所有患者进行药敏试验,根据抗生素耐药性将患者分为耐药组(n＝112)和非耐药组(n＝46)。比较两组患者咽拭子MPDNA载量指数(MPLI)及23sRNA基因2063位点突变率,分析患者MPLI与临床指标的关系,采用ROC曲线分析MPLI对耐药MP肺炎的诊断价值,并分析患者MPLI与23sRNA基因2063位点突变的相关性。结果耐药组MPLI低于非耐药组(t=4.373,P<0.001);MPLI诊断耐药MP肺炎的AUC为0.698,截点值为5.16;MPLI阳性组在退热时间≥3 d、咳嗽咯痰消失时间≥5 d、胸部阴影消失时间≥10 d、合并肺外并发症方面的人数比例大于阴性组(χ²=17.584、19.237、44.724、11.075,P<0.001);经多元Logistics回归分析得,退热时间≥3 d、咳嗽咳痰消失时间≥5 d、胸部阴影消失时间≥10 d、合并肺外并发症是影响MP肺炎患儿MPLI表达的相关因素(OR=1.420、1.573、1.670、1.598,P<0.001);耐药组23sRNA基因2063位点基因突变率高于非耐药组(χ²=52.484,P<0.001);MP肺炎患儿MPLI表达水平与23sRNA基因2063位点突变呈负相关(r=-0.538,P<0.001)。结论耐药肺炎支原体患儿MPLI表达与临床症状消失时间等临床指标有关,与23sRNA基因2063位点突变率呈负相关,且MPLI表达对耐药MP肺炎具有诊断价值。

Abstract

Objective To explore the correlation between DNA load of drug-resistance mycoplasma pneumonia(MP) and 23sRNA mutation at 2063 locus in children, in order to provide evidence for the treatment of MP pneumonia. Methods A total of 158 children with MP pneumonia who were treated in Nantong First People's Hospital from December 2017 to December 2019 were enrolled in this study.The drug sensitivity tests were performed on all patients.According to the results of drug-resistance to antibiotics, patients were divided into resistance group(n=112) and non-resistance group(n=46).The MP load index(MPLI) and mutation rate of 23sRNA gene at 2063 locus were compared between resistance group and non-resistance group.The relationship between MPLI and clinical indexes was analyzed.The diagnostic value of MPLI for drug-resistance MP pneumonia was analyzed by ROC curves.The correlation between MPLI and mutation of 23sRNA gene at 2063 locus was analyzed. Results MPLI in resistance group was significantly lower than that in non-resistance group(t=4.373, P<0.001).AUC and cut-off value of MPLI for diagnosis of drug-resistance MP pneumonia were 0.698 and 5.16, respectively.The proportion of cases with defervescence time not shorter than 3 days, disappearance time of cough and expectoration not shorter than 5 days, disappearance time of chest shadow not shorter than 10 days and extrapulmonary complications in positive MPLI group was higher than that in negative MPLI group(χ²=17.584, 19.237, 44.724, 11.075, P<0.001).Multivariate Logistics regression analysis showed that defervescence time ≥3 days, disappearance time of cough and expectoration ≥5 days, disappearance time of chest shadow ≥10 days and extrapulmonary complications were influencing factors of MPLI expression in children with MP pneumonia(OR=1.420, 1.573, 1.670, 1.598, P<0.001).The mutation rate of 23sRNA gene at 2063 locus in resistance group was significantly higher than that in non-resistance group(χ²=52.484, P<0.001).The expression level of MPLI was negatively correlated with 23sRNA gene mutation at 2063 locus(r=-0.538, P<0.001). Conclusions The expression of MPLI is related to clinical indexes such as disappearance time of clinical symptoms in children with MP pneumonia, which is negatively related to the mutation rate of 23sRNA gene at 2063 locus.MPLI expression is of diagnostic value for drug-resistance MP pneumonia.

导出引用

朱美君, 季菊花, 朱洁, 宋磊, 周峰, 赵金华. 儿童耐药肺炎支原体DNA载量与23sRNA基因2063位点突变的相关性分析[J]. 中国儿童保健杂志. 2021, 29(9): 1017-1020 https://doi.org/10.11852/zgetbjzz2020-1544

ZHU Mei-jun, JI Ju-hua, ZHU Jie, SONG Lei, ZHOU Feng, ZHAO Jin-hua. Study on the correlation between DNA load of drug-resistance mycoplasma pneumoniae and 23sRNA mutation at 2063 locus in children[J]. Chinese Journal of Child Health Care. 2021, 29(9): 1017-1020 https://doi.org/10.11852/zgetbjzz2020-1544

中图分类号： R725.6

参考文献

[1] 刘调侠, 张晓瓒, 李延琴.儿童肺炎支原体感染及耐药检测与分析[J].西部医学, 2016, 28(11):1598-1602.
[2] Kumar S,Garg IB, Sethi GR, et al.Detection of immunoglobulin M and immunoglobulin G antibodies to Mycoplasma pneumoniae in children with community-acquired lower respiratory tract infections[J].Indian J Pathol Microbiol, 2018, 61(2):214-218.
[3] 张慧芬, 白海涛, 李基明,等.肺炎支原体肺炎患儿肺炎支原体耐药性与DNA载量和基因型的关系研究[J].中国当代儿科杂志, 2017, 19(11):1180-1184.
[4] 中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会.儿童社区获得性肺炎管理指南(2013修订)(下)[J].中华儿科杂志, 2013, 51(11):856-862.
[5] 马玉楠.体外生物诊断试剂申报技术要求[J].中国新药杂志, 2003, 12(6):482-485.
[6] 潘芬, 孟磊俊, 秦惠宏, 等.儿童肺炎支原体23SrRNA基因位点突变检测分析[J].国际检验医学杂志, 2017, 38(6):760-762.
[7] 王亚坤, 高文杰, 王伟,等.肺炎支原体突变敏感性分子开关检测对抗菌药物敏感性检测的作用研究[J].中国微生态学杂志, 2016, 28(8):926-929.
[8] 叶芸, 李苏亮, 姜萍, 等.肺炎支原体23SrRNA基因突变位点与耐药表型的分析[J].检验医学, 2013, 28(1):11-16.
[9] 陆燕, 吴鸣, 章爱莲, 等.儿童重症肺炎支原体肺炎临床特征及耐药基因突变研究[J].浙江医学教育, 2018, 17(1):52-54.
[10] 张涛, 王波, 王穗琼, 等.儿童肺炎支原体的耐药性与临床用药相关性研究[J].中华妇幼临床医学杂志(电子版), 2014, 10(1):28-33.
[11] Zhou Z, Li X, Chen X, et al.Comparison of P1 and 16SrRNA genes for detection of Mycoplasma pneumoniae by nested PCR in adults in Zhejiang, China[J].J Infec Dev Ctries, 2015, 9(3):244-253.
[12] 林艳, 马微, 李桂艳,等.医院儿童肺炎支原体的耐药性变迁分析[J].中国病原生物学杂志, 2017, 12(6):92-95.
[13] Copete AR, Aguilar YA, Rueda ZV, et al.Genotyping and macrolide resistance of, Mycoplasma pneumoniae, identified in children with community-acquired pneumonia in Medellín, Colombia[J].Int J Infec Dis, 2018, 66(2):113-120.
[14] 郭艳霞, 冯艳芳, 沈丹华, 等.DNA载量和基因型检测在MP肺炎患儿治疗中的临床作用研究[J].广西医科大学学报, 2019, 36(6):904-908.
[15] 朱美君, 宋磊, 周峰,等.23S rRNA基因突变与儿童肺炎支原体耐药机制相关性[J].海南医学, 2018, 29(3):75-78.
[16] 黎燕, 钟礼立, 张兵,等.23SrRNA V区A2063G基因突变的肺炎支原体肺炎患儿临床特征分析[J].临床儿科杂志, 2018, 36(8):7-12.